Advances Research on C-MYC Proto-oncogene in Multiple Myeloma -Review.
10.7534/j.issn.1009-2137.2016.04.053
- Author:
He HUANG
1
;
Wen-Jian GUO
1
;
Ron-Xin YAO
2
Author Information
1. Department of Hematology, The Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University, Wenzhou 200025, Zhejiang Province, China.
2. Department of Hematology, The Second Affiliated Hospital & Yuying Children's Hospital of Wenzhou Medical University, Wenzhou 200025, Zhejiang Province, China.E-mail:Yaorx828@163.com.
- Publication Type:Journal Article
- MeSH:
Chromosome Aberrations;
Genes, myc;
Humans;
Multiple Myeloma;
Plasma Cells;
Proto-Oncogene Proteins c-myc
- From:
Journal of Experimental Hematology
2016;24(4):1248-1251
- CountryChina
- Language:Chinese
-
Abstract:
Multiple myeloma(MM) as one of the most common tumors of hmatologic system, is characterized by malignant proliferation of plasma cells, and the chemotherapy is the main therapeutic method. MM is an incurable disease because of drug-resistance of MM cells. Although the pathogenesis of MM remains unknown, the chromosome abnormalities exit in half of the patients, particularly the highly expressed gene C-MYC. Furthermore, plenty of clinical researches indicated a high expression level of C-MYC implied worse progression and/or poor prognosis of MM. Recently, the work exploiting the compounds targeting MYC has made substantial progress, even in the MM therapy. In this article, briefly the recent advances of the research on C-MYC proto-oncogene in multiple myeloma are reviewed.
